What is the current Basilea Pharmaceutica AG Allschwil market capitalization?
The current market capitalization of Basilea Pharmaceutica AG Allschwil is 500.64 M CHF.
Basilea Pharmaceutica AG Allschwil Market capitalization 2024
Basilea Pharmaceutica AG Allschwil Market capitalization
500.64 M CHF
Ticker
BSLN.SW
ISIN
CH0011432447
WKN
A0B9GA
In 2024, Basilea Pharmaceutica AG Allschwil's market cap stood at 500.64 M CHF, a -0.57% increase from the 503.52 M CHF market cap in the previous year.
The Basilea Pharmaceutica AG Allschwil Market capitalization history
| YEAR | REVENUE (undefined CHF) | GROSS MARGIN (%) | NET INCOME (undefined CHF) |
|---|---|---|---|
| 2028e | 222.5 | 58,80 | 77.11 |
| 2027e | 244.92 | 53,42 | 78.72 |
| 2026e | 244.62 | 53,49 | 56.78 |
| 2025e | 228.98 | 57,14 | 54.11 |
| 2024e | 194.8 | 67,17 | 38.89 |
| 2023 | 157.63 | 83,00 | 10.45 |
| 2022 | 147.77 | 83,35 | 12.15 |
| 2021 | 148.12 | 83,75 | -6.83 |
| 2020 | 127.63 | 81,15 | -14.72 |
| 2019 | 134.38 | 85,96 | -22.42 |
| 2018 | 132.56 | 84,69 | -31.35 |
| 2017 | 101.52 | 91,11 | -19.36 |
| 2016 | 65.98 | 91,90 | -51.29 |
| 2015 | 51.65 | 253,30 | -61.6 |
| 2014 | 42.5 | 307,87 | -41.55 |
| 2013 | 41 | 100,00 | -33 |
| 2012 | 57.9 | 92,40 | -53 |
| 2011 | 66.7 | 96,40 | -57.6 |
| 2010 | 116.2 | 98,02 | 107.6 |
| 2009 | 26.5 | 93,96 | -120.7 |
| 2008 | 11.8 | 97,46 | -143.5 |
| 2007 | 7.9 | 100,00 | -126.8 |
| 2006 | 7.4 | 1768,11 | -85.1 |
| 2005 | 30.5 | 428,98 | -49.6 |
| 2004 | 0.3 | 43613,33 | -75.5 |
Basilea Pharmaceutica AG Allschwil Aktienanalyse
What does Basilea Pharmaceutica AG Allschwil do?
Basilea Pharmaceutica AG is a leading biopharmaceutical company based in Basel, Switzerland. It was founded in 2000 and focuses on the research, development, and marketing of innovative drugs for the treatment of infectious diseases, cancer, and dermatological conditions. The company operates globally and currently employs over 200 employees. Basilea's main focus is on developing drugs that meet the specific needs of patients and medical professionals. It works closely with its partners and customers to ensure that its products meet the highest quality standards and meet the demands of patients. Basilea has two main divisions: infections and oncology. The company has a strong expertise in the development of antibiotics and antifungal drugs. One of its most well-known products is the antibiotic Ceftobiprol, which is used to treat bacterial infections such as pneumonia, skin, and bone infections. Another promising product is Isavuconazole, an antifungal drug used to treat fungal infections. In oncology, the business is divided into two important areas: the development and marketing of cancer drugs, and collaboration with other companies to develop tailored cancer therapies. The company works closely with other leading companies such as Pfizer, Roche, and GSK to expand its expertise in cancer research and development. Basilea's business model is based on the development of innovative drugs that meet the needs of patients and doctors. The company invests heavily in its research and development and aims to develop ethically sound and effective solutions for controlling infectious diseases and cancer. Through strategic partnerships and targeted marketing, it works to market its products worldwide and strengthen its position in the rapidly changing pharmaceutical market. Basilea sees itself as an innovative company that establishes itself in the market and plays a leading role in the industry. Its success is based on the concept of innovation, commitment, and growth. The company is committed to improving the quality of life for patients around the world by focusing on the development of new drugs that help fulfill important medical needs. Basilea Pharmaceutica AG remains committed to striving for excellence and innovation together with its partners and customers to advance the development of new treatment options. With this focus, Basilea will continue to play an important role in the industry and bring innovative drugs to the market that improve patients' lives and make the world a better place. Basilea Pharmaceutica AG Allschwil ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Basilea Pharmaceutica AG Allschwil's Market Capitalization
Basilea Pharmaceutica AG Allschwil's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Basilea Pharmaceutica AG Allschwil's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Basilea Pharmaceutica AG Allschwil's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Basilea Pharmaceutica AG Allschwil’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Basilea Pharmaceutica AG Allschwil Stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Basilea Pharmaceutica AG Allschwil.
How has the market capitalization of Basilea Pharmaceutica AG Allschwil developed in recent years?
The market capitalization of Basilea Pharmaceutica AG Allschwil has increased/decreased by -0.57% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Basilea Pharmaceutica AG Allschwil?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Basilea Pharmaceutica AG Allschwil?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Basilea Pharmaceutica AG Allschwil have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Basilea Pharmaceutica AG Allschwil pay?
Over the past 12 months, Basilea Pharmaceutica AG Allschwil paid a dividend of 5 CHF . This corresponds to a dividend yield of about 11.98 %. For the coming 12 months, Basilea Pharmaceutica AG Allschwil is expected to pay a dividend of 0 CHF.
What is the dividend yield of Basilea Pharmaceutica AG Allschwil?
The current dividend yield of Basilea Pharmaceutica AG Allschwil is 11.98 %.
When does Basilea Pharmaceutica AG Allschwil pay dividends?
Basilea Pharmaceutica AG Allschwil pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Basilea Pharmaceutica AG Allschwil?
Basilea Pharmaceutica AG Allschwil paid dividends every year for the past 0 years.
What is the dividend of Basilea Pharmaceutica AG Allschwil?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Basilea Pharmaceutica AG Allschwil located?
Basilea Pharmaceutica AG Allschwil is assigned to the 'Health' sector.
Wann musste ich die Aktien von Basilea Pharmaceutica AG Allschwil kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Basilea Pharmaceutica AG Allschwil from 6/21/2013 amounting to 5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/11/2013.
When did Basilea Pharmaceutica AG Allschwil pay the last dividend?
The last dividend was paid out on 6/21/2013.
What was the dividend of Basilea Pharmaceutica AG Allschwil in the year 2023?
In the year 2023, Basilea Pharmaceutica AG Allschwil distributed 0 CHF as dividends.
In which currency does Basilea Pharmaceutica AG Allschwil pay out the dividend?
The dividends of Basilea Pharmaceutica AG Allschwil are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Basilea Pharmaceutica AG Allschwil
Our stock analysis for Basilea Pharmaceutica AG Allschwil Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Basilea Pharmaceutica AG Allschwil Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Basilea Pharmaceutica AG Allschwil Revenue
- Basilea Pharmaceutica AG Allschwil Net Income
- Basilea Pharmaceutica AG Allschwil P/E
- Basilea Pharmaceutica AG Allschwil P/S
- Basilea Pharmaceutica AG Allschwil EBIT
- Basilea Pharmaceutica AG Allschwil Dividend
- Basilea Pharmaceutica AG Allschwil Stocks
- Basilea Pharmaceutica AG Allschwil Market capitalization
- Basilea Pharmaceutica AG Allschwil Debt
- Basilea Pharmaceutica AG Allschwil Liabilities
- Basilea Pharmaceutica AG Allschwil Equity
- Basilea Pharmaceutica AG Allschwil AAQS
- Basilea Pharmaceutica AG Allschwil Employees
- Basilea Pharmaceutica AG Allschwil ROE
- Basilea Pharmaceutica AG Allschwil ROA
- Basilea Pharmaceutica AG Allschwil ROCE
